2020
DOI: 10.1007/s10067-020-05057-9
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 23 publications
0
5
0
Order By: Relevance
“…8,24,25 A similar pattern is seen in real-world studies, with patients with inadequate response or intolerance to TNFα inhibitors reporting lower effectiveness and greater rates of treatment discontinuation or switching compared with patients who are naive to TNFα inhibitors. 26,27 Given the lower effectiveness in this population, as well as the continued adoption of TNFα inhibitor treatments and TNFα inhibitor biosimilars as first-line therapies, efficacy in patients with inadequate response or intolerance to TNFα inhibitors with psoriatic arthritis becomes increasingly relevant. The efficacy of bimekizumab in this difficult-totreat population of patients with inadequate response or intolerance to TNFα inhibitors could be due to an enrichment of patients with IL-17F-dependent signalling driving their disease, which cannot be inhibited by TNFα inhibitors or other treatments that only target IL-17A.…”
Section: Discussionmentioning
confidence: 99%
“…8,24,25 A similar pattern is seen in real-world studies, with patients with inadequate response or intolerance to TNFα inhibitors reporting lower effectiveness and greater rates of treatment discontinuation or switching compared with patients who are naive to TNFα inhibitors. 26,27 Given the lower effectiveness in this population, as well as the continued adoption of TNFα inhibitor treatments and TNFα inhibitor biosimilars as first-line therapies, efficacy in patients with inadequate response or intolerance to TNFα inhibitors with psoriatic arthritis becomes increasingly relevant. The efficacy of bimekizumab in this difficult-totreat population of patients with inadequate response or intolerance to TNFα inhibitors could be due to an enrichment of patients with IL-17F-dependent signalling driving their disease, which cannot be inhibited by TNFα inhibitors or other treatments that only target IL-17A.…”
Section: Discussionmentioning
confidence: 99%
“…RWE are scarce about SEK and UST in PsA. Two studies reported the persistence of UST in PsA [16,18]. Azuaga et al showed a 12-month persistence rate of 64.1% in 201 Spanish patients with PsA treated with UST.…”
Section: Discussionmentioning
confidence: 99%
“…bDMARD-naïve patients and those treated with one prior TNFi had a significantly higher 12month persistence rate than patients treated with two or more prior TNFi. Discontinuation due to inefficacy was the most frequent cause (72.9%) [18]. Walsh et al analysed data of patients who initiated therapy with a bDMARD for PsA obtained from the Optum Research FIG.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This is likely to have been due to the small number of patients with arthritis in those series, which meant that a real relationship of a broadly similar magnitude to the one we noted would not have been statistically significant with such a small sample size (beta-type error). It has recently been reported that retention rate of ustekinumab 90 mg was 76.1% after a median time of 12 months follow up in patients with psoriatic arthritis in a real-world setting [40]. Studies investigating ustekinumab survival on a large cohort of patients with psoriatic arthritis, in order to replicate these findings, are required.…”
Section: Discussionmentioning
confidence: 99%